Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | HTR7 | P34969 | 1/20 | 0.69 |
| ▸ | HTR6 | P50406 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11075546 | 0.90 | HTR1A (0.66) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL11083599 | 0.89 | HTR1A (0.63) | HTR1ADRD2HTR2AHTR7HTR6 | |
| Hydrochloric Acid SCHEMBL11085460 | 0.88 | HTR1A (0.62) | HTR1ADRD2HTR2AHTR7HTR6 | |
| Hydrochloric Acid SCHEMBL11081260 | 0.88 | HTR1A (0.64) | HTR1ADRD2HTR2AHTR7HTR6 | |
| Tiospirone SCHEMBL29356145 | 0.88 | — | — | |
| Tiospirone SCHEMBL78696 | 0.88 | — | — | |
| Tiospirone SCHEMBL122406 | 0.87 | — | — | |
| SCHEMBL13532488 | 0.87 | — | — | |
| Tiospirone SCHEMBL11081111 | 0.86 | — | — | |
| SCHEMBL10471393 | 0.86 | HTR1A (0.64) | HTR1ADRD2HTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4411901-A | ANTIPSYCHOTICS | MEAD JOHNSON & COMPANY (US) | 1983-10-25 | — | — | US | claimed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-4452799-A | NEUROLEPTIC AGENTS | MEAD JOHNSON & COMPANY (US) | 1984-06-05 | — | — | US | disclosed |
| US-4411901-A | ANTIPSYCHOTICS | MEAD JOHNSON & COMPANY (US) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR1A 7/4885DRD2 242/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.